Combination regimen of 2-chlorodeoxyadenosine (Cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 32, Issue 3-4, 1999, Pages 359-363

  Robak, Tadeusz ^a   Gora Tybor, Joanna ^b   Urbańska Ryś, Halina ^b   Krykowski, Euzebiusz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NONE

Author keywords

2 chlorodeoxyadenosine; Dexamethasone; Mitoxantrone; Non Hodgkin's lymphoma

Indexed keywords

CLADRIBINE; DEXAMETHASONE; LACTATE DEHYDROGENASE; MITOXANTRONE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032982488     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909167397     Document Type: Article

References (17)

1. Saven A. and Piro L.D. (1994) Newer purine analogues for the treatment of hairy cell leukemia. N.Engl.J.Med., 330, 691-697.
2. Pott-Hoeck C. and Hiddeman W. (1995) Purine analogs in the treatment of low-grade lymphomas and lymphocytic leukemias. Ann.Oncol., 6, 421-433.
3. Juliusson G. and Liliemark J. (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol., 11, 679-689.
4. Robak T., Gora-Tybor J., Krykowski E., Walewski J.A., Borawska A., Pluzanska A., Potemski P., Hellmann A., Zaucha J.M., Konopka L., Ceglarek B., Durzynski T., Sikorska A., Michalak K., Urasinski J., Opalinska J., Dmoszynska A., Adamczyk-Cioch M.D., Kuratowska Z., Dwilewicz J., Bogurodzki P., Deren M. and Grieb P. (1997). Activity of 2-chlorodeoxyadenosine in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk.Lymph., 26, 99-105.
5. Robak T., Blasinska-Morawiec M., Krykowski E., Hansz J., Komarnicki M., Kazimierczak M., Konopka L., Maj S., Hellmann A., Zaucha J.M., Urasinski J., Zdziarska B., Kotlarek-Haus S., Usnarska-Zubkiewicz L., Kuratowska Z., Dwilewicz-Trojaczek J., Holowiecki J., Krawczyk-Kulis M., and Grieb P. (1996) 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk.Lymph., 22, 107-111.
6. Szmigielska A., Gora-Tybor J. and Robak T. (1996). Influence of 2-chlorodeoxyadenosine alone and in combination with cytosine arabinoside on murine leukemias L1210 and P388. Cancer J., 9, 319-322.
7. Telfieri A., Witzig T.E., Reid J.M., Li C-Y., Amos M.M. (1994) Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J.Clin.Oncol., 12, 569-574.
8. Begleiter A, Wang H., Verburg L., Lee K., Israels L.G., Mowat M.R.A. and Johnston J.B. (1996) In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia, 10, 1959-1965.
9. Robak T. and Korycka A. (1996). The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon α (IFNα) or interferon γ (IFNγ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in in vitro cultures. Leuk. Lymph., 21, 161-168.
10. Gora-Tybor J. and Robak T. (1997). Does interleukin-2 enhance the antitumor activity of 2-chlorodeoxyadenosine? Cancer J., 10, 171-174.
11. Robak T., Blasinska-Morawiec M., Blonski J.Z., Krykowski E., Komarnicki M., Trepinska E., Kazmierczak M., Hansz J., Dmoszynska A., Rolinski J., Konopka L., Skotnicki A.B., Nowak W.S., Kotlarek-Haus S, Zdziarska B. and Urasinski J. (1997). The effect of 2-hour infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur. J. Cancer 33, 2347-2351.
12. Mc Laughlin P., Hagemeister F.B., Romaguera J.E., Sarris A.H., Pate O., Younes A., Swan F., Keating M. and Cabanillas F. (1996). Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol., 14, 1262-1268.
13. Saven A., Lee T., Kosty M. and Piro L.D. (1996). Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J. Clin. Oncol., 14, 2139-2144.
14. Stansfeld A.G., Diebold J., Kapanci Y., Kelenyi G., Lennert K., Mioduszewska O., Noel H., Rilke F., Sundstrom C., van Unnik J.A.M. and Wright D.H. (1988). Updated Kiel classification for lymphomas. Lancet, 1, 292-293.
15. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., Mc Fadden E.T. and Carbone P.P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5, 649-655.
16. Faulds D., Balfour J.A., Chrisp P. and Langtry H.D. (1991). Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 41, 400-449.
17. Liliemark J., Porwit A. and Juliusson G. (1997). Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk. Lymph., 25, 313-318.